S*Bio have initated a Phase I/II trial of JAK2 inhibitor SB1518 in Chronic Idiopathic Myelofibrosis diseases including Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera and Essential Thrombocythemia
Filed under: kinase | Tagged: JAK2, kinase, s bio, SB-1518, SB1518, sbio | Comments Off